Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Sarepta Therapeutics (SRPT)

Sarepta Therapeutics (SRPT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 12,223,214
  • Shares Outstanding, K 77,989
  • Annual Sales, $ 380,830 K
  • Annual Income, $ -715,080 K
  • 60-Month Beta 1.84
  • Price/Sales 32.40
  • Price/Cash Flow N/A
  • Price/Book 10.77

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/20
See More
  • Average Estimate -1.73
  • Number of Estimates 8
  • High Estimate -1.06
  • Low Estimate -2.01
  • Prior Year -3.74
  • Growth Rate Est. (year over year) +53.74%

Price Performance

See More
Period Period Low Period High Performance
1-Month
148.02 +7.34%
on 07/30/20
175.00 -9.21%
on 07/20/20
-3.86 (-2.37%)
since 07/02/20
3-Month
119.59 +32.86%
on 05/06/20
175.00 -9.21%
on 07/20/20
+39.45 (+33.03%)
since 05/05/20
52-Week
72.05 +120.53%
on 09/26/19
175.00 -9.21%
on 07/20/20
+16.19 (+11.35%)
since 08/05/19

Most Recent Stories

More News
Sarepta Therapeutics (SRPT) Reports Q2 Loss, Tops Revenue Estimates

Sarepta Therapeutics (SRPT) delivered earnings and revenue surprises of -6.63% and 22.25%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

SRPT : 158.89 (+1.38%)
Sarepta Therapeutics: 2Q Earnings Snapshot

CAMBRIDGE, Mass. (AP) _ Sarepta Therapeutics Inc. (SRPT) on Wednesday reported a loss of $150.8 million in its second quarter.

SRPT : 158.89 (+1.38%)
Sarepta Therapeutics Announces Second Quarter 2020 Financial Results and Recent Corporate Developments

- Net product sales of $111.3 million, an 18% increase over same quarter of prior year -

SRPT : 158.89 (+1.38%)
Should You Invest in the Invesco Dynamic Biotechnology Genome ETF (PBE)?

Sector ETF report for PBE

PBE : 60.84 (+0.16%)
REGN : 624.52 (-3.69%)
AMGN : 241.47 (-0.87%)
SRPT : 158.89 (+1.38%)
IBB : 137.28 (-0.29%)
XBI : 114.39 (+0.72%)
What Awaits Selecta Biosciences (SELB) This Earnings Season?

In the absence of any marketed drugs, investor focus is likely to be on Selecta Biosciences' (SELB) lead pipeline candidate, SEL-212 on the second-quarter conference call.

TBIO : 15.17 (-1.43%)
SRPT : 158.89 (+1.38%)
ACRX : 1.1400 (+0.88%)
SELB : 2.78 (+6.11%)
Drug/Biotech Stock Q2 Earnings on Aug 5: REGN, MRNA & More

Let us take a look at five drug/biotech companies, REGN, MRNA, SRPT, ACAD and HZNP, which are gearing up for their earnings release.

REGN : 624.52 (-3.69%)
MRNA : 75.80 (-3.39%)
SRPT : 158.89 (+1.38%)
HZNP : 76.38 (+23.61%)
ACAD : 42.87 (-1.49%)
Gene Therapy Market to Reach USD 35.67 Billion by 2027; Rising Prevalence of Cancer to Bolster Growth, says Fortune Business Insights(TM)

The global gene therapy market is set to gain momentum from the rising incidence of different types of cancer. The field of this therapy is undergoing several technological advancements that would help...

AMGN : 241.47 (-0.87%)
GILD : 69.00 (-2.65%)
GSK : 41.21 (-0.07%)
JAZZ : 122.24 (+10.64%)
SRPT : 158.89 (+1.38%)
ONCE : 110.05 (-3.10%)
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on July 31, 2020 that were previously approved by the Compensation Committee...

SRPT : 158.89 (+1.38%)
Sarepta Therapeutics to Announce Second Quarter 2020 Financial Results and Recent Corporate Developments on August 5, 2020

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report second quarter 2020 financial results after the Nasdaq Global Market closes on Wednesday,...

SRPT : 158.89 (+1.38%)
SmarTrend Watching for Potential Rebound in Shares of Sarepta Therapeu After 2.83% Loss

Sarepta Therapeu (NASDAQ:SRPT) traded in a range yesterday that spanned from a low of $154.41 to a high of $160.42. Yesterday, the shares fell 2.8%, which took the trading range below the 3-day low of...

SRPT : 158.89 (+1.38%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade SRPT with:

Business Summary

Sarepta Therapeutics, Inc. focuses on the discovery and development of RNA-based therapeutics for the treatment of rare and infectious diseases. The Company's diverse pipeline includes its lead program eteplirsen, for Duchenne muscular dystrophy. Sarepta Therapeutics, Inc., formerly known as AVI BioPharma,...

See More

Key Turning Points

2nd Resistance Point 162.92
1st Resistance Point 160.90
Last Price 158.89
1st Support Level 155.47
2nd Support Level 152.06

See More

52-Week High 175.00
Last Price 158.89
Fibonacci 61.8% 135.67
Fibonacci 50% 123.53
Fibonacci 38.2% 111.38
52-Week Low 72.05

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar